Promising combo shrinks stomach tumors before surgery in early trial
NCT ID NCT05507658
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tested giving the immunotherapy drug tislelizumab along with chemotherapy (XELOX) before surgery to people with a certain type of stomach or gastroesophageal junction cancer. The goal was to see if this combination could shrink tumors more effectively and safely before the main operation. The trial involved 28 adults with locally advanced cancer and looked at how many patients had a major response to the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710000, China
Conditions
Explore the condition pages connected to this study.